Stockscreener 앱 받기
1.68
2.42%
0.03
시간 외 거래:
1.69
0.01
+0.60%
전일 마감가:
$1.65
열려 있는:
$1.62
하루 거래량:
71,019
Relative Volume:
0.65
시가총액:
$91.96M
수익:
-
순이익/손실:
$-21.38M
주가수익비율:
-4.3077
EPS:
-0.39
순현금흐름:
$-25.19M
1주 성능:
+9.74%
1개월 성능:
+13.42%
6개월 성능:
+104.82%
1년 성능:
+40.83%
1일 변동 폭
$1.62
$1.732
1주일 범위
$1.46
$1.74
52주 변동 폭
$0.51
$2.86
코넥트 바이오파마 Stock (CNTB) Company Profile
명칭
Connect Biopharma Holdings Ltd
전화
858-727-1040
주소
3580 CARMEL MOUNTAIN ROAD, SUITE 200, SAN DIEGO
CNTB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CNTB
Connect Biopharma Holdings Ltd
|
1.68 | 91.96M | 0 | -21.38M | -25.19M | -0.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.67 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.00 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.47 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.48 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.77 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
코넥트 바이오파마 Stock (CNTB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-31 | 개시 | BTIG Research | Buy |
| 2025-06-12 | 개시 | H.C. Wainwright | Buy |
| 2024-03-04 | 개시 | H.C. Wainwright | Buy |
| 2021-04-13 | 개시 | Jefferies | Buy |
| 2021-04-13 | 개시 | Piper Sandler | Overweight |
| 2021-04-13 | 개시 | SVB Leerink | Outperform |
모두보기
코넥트 바이오파마 주식(CNTB)의 최신 뉴스
Join Connect Biopharma's Exclusive Live Investor Webinar and Q&A Session on November 3 - Bucyrus Telegraph-Forum
This Immuneering Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
Connect Biopharma stock initiated with Buy rating at BTIG on respiratory drug potential - Investing.com Nigeria
BTIG Initiates Coverage on Connect Biopharma Hldgs (CNTB) with 'Buy' Rating | CNTB Stock News - GuruFocus
Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Short Interest Update - MarketBeat
Connect Biopharma (NASDAQ:CNTB) Stock Price Down 3.8%What's Next? - MarketBeat
All In Solutions Detox Enhances California Center Recovery Environment Through Tranquil Setting - The News Journal
RestoPros of Southwest Florida Expands Damage Restoration Services Across Multiple Counties - azcentral.com and The Arizona Republic
Connect Biopharma's (CNTB) Sell (D-) Rating Reiterated at Weiss Ratings - MarketBeat
Hyperke Growth Partners Reveals How They Help SEO Agencies with Qualified Lead Generation in Case Study - azcentral.com and The Arizona Republic
Connect Biopharma's (CNTB) "Sell (D-)" Rating Reaffirmed at Weiss Ratings - MarketBeat
Severe Asthma Pipeline 2025: Therapies Under Investigation, - openPR.com
Connect Biopharma (NASDAQ:CNTB) Stock Price Up 7.4%Still a Buy? - MarketBeat
Connect Biopharma Holdings Limited (CNTB) stock price, news, quote and history - Yahoo
October 2025's Promising Penny Stocks To Consider - Yahoo Finance
Short Interest in Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Drops By 53.6% - MarketBeat
H.C. Wainwright reiterates Buy rating on Connect Biopharma stock at $7 target By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Buy rating on Connect Biopharma stock at $7 target - Investing.com Nigeria
507mL Lung Function Improvement: Connect Bio's New Asthma Drug Shows Remarkable Results in High-Risk Patients - Stock Titan
James Huang to join CASI Pharmaceuticals board as independent director By Investing.com - Investing.com Australia
CASI Pharmaceuticals Appoints James Huang to Board of Directors - ACCESS Newswire
35-Year Biotech Veteran James Huang Joins CASI Pharma Board as Company Advances CID-103 Program - Stock Titan
Eosinophilic Asthma Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Lanier Biotherapeutics, Bio-Thera Solutions, Kinaset Therapeutics, CSPC ZhongQi Pharma - Barchart.com
Eosinophilic Asthma Pipeline 2025: Therapies, MOA Insights, - openPR.com
FY2025 EPS Estimate for Connect Biopharma Lowered by Analyst - MarketBeat
Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Sees Large Drop in Short Interest - MarketBeat
Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Short Interest Up 204.8% in August - MarketBeat
Asthma Market to Show Paltry Growth at a CAGR of 1.95% During the Forecast Period (2025-2034) | DelveInsight - Yahoo Finance
Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Sees Large Increase in Short Interest - Defense World
Connect Biopharma Announces Poster Presentations of Rademikibart at the European Respiratory Society Congress 2025 - Quiver Quantitative
New Asthma Treatment Data: Connect Biopharma's Rademikibart Shows Impact on FEV1 in Type 2 Asthma Trial - Stock Titan
Connect Biopharma completes termination of its American depositary receipt program and directly lists its ordinary shares on Nasdaq - MarketScreener
Connect Biopharma Ends ADR Program, Moves to Direct Nasdaq Listing; Shares Up Premarket - MarketScreener
Connect Biopharma Completes Termination of its American - GlobeNewswire
Biotech Connect Biopharma Completes Strategic Shift to Direct Nasdaq Listing for U.S. Growth - Stock Titan
COPD Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Genentech, GlaxoSmithKline, Verona Pharma, Regeneron Pharma, Sanofi, MedImmune, EpiEndo Pharma, Tetherex Pharma - Barchart.com
3 Penny Stocks To Watch With Market Caps Over $100M - simplywall.st
Connect Biopharma (CNTB) Expected to Announce Quarterly Earnings on Friday - Defense World
Connect Biopharma Holdings Limited to Participate in Upcoming Healthcare Conferences - Quiver Quantitative
Clinical-Stage Biotech Connect Biopharma Announces Key September Investor Conference Appearances - Stock Titan
코넥트 바이오파마 (CNTB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.29%
0.56%
자본화:
|
볼륨(24시간):